Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative Metastatic Breast Cancer and Germline BRCA1/2 Mutations: An Observational Study Using Flatiron Electronic Health Record (EHR) Database
Overview
- Phase
- Not Applicable
- Intervention
- Talazoparib
- Conditions
- Metastatic Breast Cancer
- Sponsor
- Pfizer
- Enrollment
- 33
- Locations
- 1
- Primary Endpoint
- Time to Treatment Failure (TTF) for Talazoparib
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
This non-interventional retrospective study will describe real-world treatment patterns and clinical outcomes among adults with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations who initiated talazoparib as a first or later line of therapy. Patients will be identified from the Flatiron Electronic Health Record database.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
- •Diagnosed with breast cancer (ICD-9 174.x or 175.x or ICD-10 C50x)
- •At least two visits in the Flatiron database on or after January 1, 2011
- •Pathology consistent with breast cancer
- •Has evidence of stage IV or recurrent metastatic breast cancer with a metastatic diagnosis date on or after January 1,
- •This includes patients who were diagnosed with stage IV at diagnosis or were diagnosed with earlier stage disease, then developed a distant metastasis later on, or had recurrence of the disease via a distant metastasis
- •Confirmed receipt of talazoparib as treatment for mBC via abstraction initiated between January 1, 2018 and September 30, 2020
- •HER2 negative test result on or before the start of patient's first talazoparib-containing line of therapy, as defined by Flatiron's line of therapy rules
- •BRCA1, BRCA2, BRCA1 and BRCA2 germline mutation, or BRCA germline mutation not otherwise specified, identified on or before the start date of patient's first talazoparib-containing line of therapy, as defined by Flatiron's line of therapy business rules
- •Age 18 years or older at the time of first talazoparib-containing line of therapy
Exclusion Criteria
- •Lacking relevant unstructured documents in the Flatiron database for review by the abstraction team
- •Receipt of drug as part of a clinical trial (captured in the database as "clinical study drug" without additional information about active ingredient or whether the patient received placebo), defined as any non-cancelled order, administration, or oral episode for a drug used in a clinical trial, on or prior to start of first talazoparib line of therapy, as defined by Flatiron's line of therapy business rules
Arms & Interventions
Talazoparib-treated adults with HER2- gBRCAm mBC
Adult patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations who initiated talazoparib treatment in first-line or later line of therapy between January 1, 2018 and September 30, 2020.
Intervention: Talazoparib
Outcomes
Primary Outcomes
Time to Treatment Failure (TTF) for Talazoparib
Time Frame: Index date up to talazoparib discontinuation or at the end of follow-up or date of data cut-off (30-September-2020), maximum up to approximately 2.9 years; data retrieved and studied approximately 6.14 months of this study
TTF was defined as the time from initiation of talazoparib to discontinuation for any reason, which included disease progression, treatment toxicity, and death. Participants who were still on therapy at the end of follow-up (earliest of last participant-level structured or abstracted activity \[i.e., the last record of participant vitals, medication administrations, or reported laboratory tests/results, or abstracted end date of oral medications\] or date of data cut-off \[30 September 2020\]) were censored. Index date was defined as the date first talazoparib-containing line of therapy between 01-Jan-2018 to 30-Sep-2020. Median was analyzed using the Kaplan-Meier method.